Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Morgan Stanley
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “equal weight” rating reiterated by equities research analysts at Morgan Stanley in a research note issued to investors on Monday.
Several other research analysts have also commented on the stock. Credit Suisse Group lowered shares of Alnylam Pharmaceuticals to a “hold” rating and set a $50.00 price objective for the company. in a research note on Monday, March 20th. ValuEngine raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Vetr raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $72.50 price objective for the company in a research note on Thursday, March 16th. Piper Jaffray Companies set a $118.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 15th. Finally, FBR & Co reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, March 20th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $77.13.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 78.97 on Monday. The stock has a 50 day moving average of $73.05 and a 200-day moving average of $53.57. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $86.92. The company’s market capitalization is $6.81 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The company had revenue of $19 million for the quarter, compared to analysts’ expectations of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The company’s quarterly revenue was up 160.3% compared to the same quarter last year. During the same period last year, the business earned ($1.21) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.26) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/10/alnylam-pharmaceuticals-inc-alny-rating-reiterated-by-morgan-stanley.html.
In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the sale, the vice president now owns 5,625 shares of the company’s stock, valued at $393,750. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Sanofi acquired 297,501 shares of the business’s stock in a transaction on Wednesday, May 31st. The shares were bought at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The disclosure for this purchase can be found here. In the last three months, insiders have sold 64,125 shares of company stock worth $4,325,000. 4.30% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in Alnylam Pharmaceuticals by 283.6% in the first quarter. Bank of Montreal Can now owns 9,528 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 7,044 shares during the last quarter. Peregrine Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 7.5% in the first quarter. Peregrine Capital Management LLC now owns 221,909 shares of the biopharmaceutical company’s stock worth $11,723,000 after buying an additional 15,477 shares during the last quarter. Macquarie Group Ltd. boosted its stake in Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock worth $665,000 after buying an additional 1,614 shares during the last quarter. Opus Point Partners Management LLC boosted its stake in Alnylam Pharmaceuticals by 97.0% in the fourth quarter. Opus Point Partners Management LLC now owns 88,784 shares of the biopharmaceutical company’s stock worth $3,324,000 after buying an additional 43,720 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock worth $2,755,000 after buying an additional 7,048 shares during the last quarter. 89.27% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.